Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. HS, a chronic, recurrent ...
Adults with moderate to severe hidradenitis suppurativa experienced substantial long-term symptom relief and quality of life ...
Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial ...
MedPage Today on MSN
Novel therapies for hidradenitis suppurativa produce rapid, deepening responses
Responses include total clearance in up to 30% of patients treated with sonelokimab, povor ...
Add Yahoo as a preferred source to see more of our stories on Google. Getty Images Raise your hand if you’ve got some drama happening in your underarms. If you often get pimples, blackheads, or larger ...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 ...
The STOP-HS data supported the submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib as a treatment for HS which are under review by the U.S. Food ...
Maybe it’s that new exercise program you’ve been following. Or maybe you just sweat a lot. Whatever the reason, you’ve noticed a bunch of red bumps on your skin lately, especially in the folds of your ...
UCB, a global biopharmaceutical company, today announced data for BIMZELX in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in ...
NEW ORLEANS -- A trio of novel therapies produced clinically significant improvements in 40% to 70% of patients with moderate to severe hidradenitis suppurativa (HS), according to data reported here.
Stocktwits on MSN
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data
Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results